Samuel Jesuadian is a health and biomedical innovation executive with deep expertise in commercialisation, advanced biomanufacturing, and AI-enabled clinical technologies. As Chief Commercial Officer of ARM Hub and as a non-executive director of Life Sciences Queensland, he leads the development of next-generation manufacturing and translational infrastructure to strengthen Australia’s life sciences capability.
Samuel has secured over $250 million in commercial contracts across industry, academia, and government, designing and delivering health-focused initiatives spanning biomedical AI acceleration, national AI adoption programs, and federated synthetic clinical data platforms to enable secure and scalable machine learning in healthcare. His work has supported more than 170 businesses in technology adoption, clinical translation, and advanced manufacturing uplift.
He is currently spearheading a CDMO platform dedicated to Defence and Medtech, in partnership with the Gold Coast Council, to establish sovereign capability in cell therapies, advanced diagnostics, and regulated biomanufacturing. His leadership integrates commercial strategy, international collaboration, and translational research to position Australia as a competitive global player in clinical technology, precision medicine, and advanced health manufacturing.
%20(1).png)
